Therapeutic antibodies to intracellular targets in cancer therapy Journal Article

  


Authors: Veomett, N.; Dao, T.; Scheinberg, D. A.
Article Title: Therapeutic antibodies to intracellular targets in cancer therapy
Abstract: Therapeutic monoclonal antibodies (mAbs) are a proven therapeutic platform, but they cannot readily cross the cell membranes to bind intracellular antigens, while some of the most important disease-associated proteins are intracellular, protected from direct mAb attack. However, the cellular processes of necrosis and major histocompatibility complex (MHC) class I antigen presentation expose epitopes from intracellular proteins to the extracellular environment or cell surface. Antibodies that exploit these processes can therefore specifically target diseased cells based on their intracellular protein content. These strategies expose important new targets for mAb therapy and expand the potential for effective therapies. © 2013 Informa UK, Ltd.
Keywords: hla; antibody therapy; tcr-like; esk1; intracellular antigens; mhc class i presentation; tcr mimic; tumor necrosis therapy
Journal Title: Expert Opinion on Biological Therapy
Volume: 13
Issue: 11
ISSN: 1471-2598
Publisher: Taylor & Francis Group  
Date Published: 2013-11-01
Start Page: 1485
End Page: 1488
Language: English
DOI: 10.1517/14712598.2013.833602
PROVIDER: scopus
PUBMED: 23991764
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84885630721&partnerID=40&md5=936ea1c6f2701de007f3fc05ed8a360a
Notes: --- - "Export Date: 1 November 2013" - "CODEN: EOBTA" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. David Scheinberg
    499 Scheinberg
  2. Tao Dao
    81 Dao
  3. Nicholas J Veomett
    10 Veomett
Related MSK Work